How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

242 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. (PubMed)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL

Full Text available with Trip Pro

2015 BMC neurology Controlled trial quality: predicted high

62. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. (PubMed)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. To evaluate the efficacy and safety of adjunctive eslicarbazepine acetate (ESL) in patients with refractory partial-onset seizures.This randomized, placebo-controlled, double-blind, parallel-group, phase III study was conducted at 173 centers in 19 countries, including the United States and Canada. Eligible patients were

Full Text available with Trip Pro

2015 Epilepsia Controlled trial quality: predicted high

63. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. (PubMed)

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. Eslicarbazepine acetate (ESL) is an anticonvulsant approved as an adjunctive therapy in adults with partial-onset seizures.To evaluate the efficacy, safety and tolerability of ESL in the treatment of acute mania and prevention of recurrence in bipolar disorder I.Two 3

2015 Journal of Affective Disorders Controlled trial quality: predicted high

64. Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate. (PubMed)

Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate. The objective of this study was to compare posttreatment seizure severity in a phase III clinical trial of eslicarbazepine acetate (ESL) as adjunctive treatment of refractory partial-onset seizures.The Seizure Severity Questionnaire (SSQ) was administered at baseline and posttreatment. The SSQ total score (TS) and component scores (frequency and helpfulness of warning signs before seizures [BS

2015 Epilepsy & behavior : E&B Controlled trial quality: uncertain

65. Aptiom (eslicarbazepine acetate) - As an add-on medication to treat seizures associated with epilepsy

Aptiom (eslicarbazepine acetate) - As an add-on medication to treat seizures associated with epilepsy Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Aptiom (Eslicarbazepine Acetate) Tablets Company: Sunovion Inc. Application No.: 022416 Approval Date: 11/08/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

66. Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Food (...) Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02288312 Recruitment Status : Completed First Posted : November 11, 2014 Results First Posted : January 8, 2015 Last Update Posted : January 8, 2015 Sponsor: Bial - Portela C S.A

2014 Clinical Trials

67. Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02281591 Recruitment Status : Completed First Posted : November 3, 2014 Results First Posted : December 3, 2014 Last Update

2014 Clinical Trials

68. Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283840 Recruitment Status : Completed First Posted

2014 Clinical Trials

69. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283827 Recruitment Status : Completed First Posted : November 5, 2014 Results First Posted : December 18, 2014 Last Update Posted : December 18, 2014 Sponsor: Bial

2014 Clinical Trials

70. A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283814 Recruitment Status : Completed First Posted : November 5, 2014 Results First Posted : December 22, 2014 Last Update Posted : December 22, 2014

2014 Clinical Trials

71. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283801 Recruitment Status : Completed First Posted : November 5, 2014 Last Update Posted : November 5, 2014 Sponsor: Bial - Portela C S.A. Information

2014 Clinical Trials

72. Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283788 Recruitment Status : Completed First Posted : November 5, 2014 Results First Posted : December 22, 2014 Last Update Posted : December 22, 2014 Sponsor

2014 Clinical Trials

73. Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02284828 Recruitment Status : Completed First Posted : November 6, 2014 Results First Posted : December 10, 2014 Last Update Posted : December 10, 2014

2014 Clinical Trials

74. Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02284854 Recruitment Status : Completed First Posted : November 6, 2014 Results First Posted : January 8, 2015 Last Update Posted : January 8, 2015 Sponsor

2014 Clinical Trials

75. Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02284880 Recruitment Status : Completed First Posted : November 6, 2014 Results First Posted : January 12, 2015 Last Update Posted : January 12, 2015

2014 Clinical Trials

76. Design of the epos study: an open-label, multicentre, non-interventional study to evaluate eslicarbazepine acetate as adjunctive treatment to one baseline antiepileptic drug in adults with partial-onset seizures. (PubMed)

Design of the epos study: an open-label, multicentre, non-interventional study to evaluate eslicarbazepine acetate as adjunctive treatment to one baseline antiepileptic drug in adults with partial-onset seizures.

2013 Neurosurgery and Psychiatry

77. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: bia-2093-301 study. (PubMed)

Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: bia-2093-301 study.

2013 Neurosurgery and Psychiatry

78. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. (PubMed)

Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs

Full Text available with Trip Pro

2013 Seizure : the journal of the British Epilepsy Association

79. A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2013 Clinical Trials

80. Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01825837 Recruitment Status : Completed First Posted : April 8, 2013

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>